Introduction

Several ion channels implicated in central and peripheral nervous system disorders, including ischemic stroke, Alzheimer’s disease, and multiple sclerosis. These channels represent critical therapeutic targets for neuroprotection, reducing neuronal damage, and managing neurodegenerative symptoms.

Ischemic Stroke Targets:

    √ Voltage-Gated Sodium Channels (Nav1.1, Nav1.2, Nav1.3, Nav1.6): Sodium channel blockers reduce metabolic demands, providing neuroprotection during ischemic events.

    √ Potassium Channels (KCNQ2/3): Activation of these channels helps stabilize neuronal excitability and prevent excitotoxicity.

    √ Acid-Sensing Ion Channels (ASIC1a): Blocking acid-induced calcium influx via ASIC1a can mitigate ischemic neuronal injury.

Neurodegeneration and Alzheimer’s Disease Targets:

    √ Voltage-Gated Potassium Channels (Kv3.4): Blockade of Kv3.4 can alleviate neurologic symptoms associated with Alzheimer’s disease.

    √ Glutamate Receptors (NMDA): NMDA receptor antagonists reduce excitotoxicity, a key contributor to neurodegenerative damage.

    √ Nicotinic Acetylcholine Receptors (nAChRα7): Activation of these receptors can enhance cognitive function and counter neurodegenerative decline.

Multiple Sclerosis Targets:

    √ Voltage-Gated Potassium Channels (Kv1.3, Kv1.5): Targeting these channels may modulate immune cell activity, reducing neuroinflammation in multiple sclerosis.

    √ Voltage-Gated Sodium Channel (Nav1.6): Implicated in the pathophysiology of demyelinating diseases, this channel represents a target for modulating disease progression.

General Neuroprotection:

    √ Calcium-Activated Potassium Channels (SK2, SK3, IK): Stabilize neuronal activity and prevent overexcitation.

    √ Chloride Channels (CLC-2, CFTR): Maintain ionic balance, reducing stress on neurons.

Transient Receptor Potential Channels (TRPC4): Involved in calcium signaling pathways linked to neuronal survival.

Neurodegeneration/stroke ion channel Portfolio

Our neurodegeneration/stroke ion channel portfolio is a curated collection of ion channels that have been implicated in the treatment and etiology of neurodegenerative diseases and stroke. This panel is designed to assess a compound's target specificity and potential off-target effects, which is crucial for the discovery of drugs that can effectively manage neurodegenerative conditions and stroke-related complications.

The Neurodegeneration/Stroke Ion Channel Portfolio is a powerful tool in the early stages of drug discovery, offering a focused approach to identifying and profiling ion channels that are critical in neurodegenerative and stroke-related conditions. By targeting these channels, we can accelerate the development of novel therapeutics with improved selectivity and efficacy.